_id
69171a8b3c536f8df23165a8
Ticker
SWOBY
Name
Swedish Orphan Biovitrum AB (publ)
Exchange
PINK
Address
Norra Stationsgatan 93A, Stockholm, Sweden
Country
USA
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Currency
USD
Website
https://www.sobi.com
Description
Swedish Orphan Biovitrum AB (publ), a biopharma company, provides medicines in the areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. The company operates through three segments: Haematology, Immunology, and Specialty Care. It offers Alprolix for haemophilia B; ALTUVOCT for the treatment and prophylaxis of bleeding in patients with haemophilia A; Aspaveli/Empaveli for treating adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet for the treatment of immune thrombocytopenia and thrombocytopenia; Elocta/Eloctate for the treatment and prophylaxis of bleeding in patients with haemophilia A; Gamifant for treating hemophagocytic lymphohistiocytosis; Kineret for the treatment of cryopyrin-associated periodic syndrome, rheumatoid arthritis, familial Mediterranean fever, deficiency of interleukin-1 receptor antagonist, and systemic juvenile idiopathic arthritis; Orfadin for hereditary tyrosinemia type 1 and alkaptonuria; Synagis for the prevention of serious lower respiratory tract infection caused by respiratory syncytial virus in infants and young children; VONJO, a kinase inhibitor indicated for the treatment of post-polycythemia vera or post-essential thrombocythemia myelofibrosis; and Zynlonta for treating adult patients with relapsed or refractory diffuse large and high grade B-cell lymphoma. The company also provides other medicines, such as Akynzeo, Aloxi, Jyseleca, Kepivance, Tegsedi, and Waylivra, as well as develops drug substances for ReFacto AF/Xyntha for Pfizer. The company has collaboration agreements with Sanofi, Apellis Pharmaceuticals, Inc., ADC Therapeutics SA, and Cartesian Therapeutics, Inc. Swedish Orphan Biovitrum AB (publ) was incorporated in 1939 and is headquartered in Stockholm, Sweden.
Last Close
17.8
Volume
-
Current Price
16.9
Change
0
Last Updated
2026-01-07T12:42:10.916Z
Image
-
Ipo Date
-
Market Cap
12294910976
Next Dividend Date
-
Dividend Frequency
-
Dividend Rate
-
Dividend Yield
0
Sentiment
0.9836374999999999
Sentiment Sources
8
Rating
1
Strong Buy
0
Buy
0
Hold
0
Sell
0
Strong Sell
1
Current Quarter
2025-06-30
Revenue
6175000000
Cost Of Revenue
1426000000
Gross Profit
4749000000
Operating Expenses
5165000000
Operating Income
1010000000
Interest Expense
-
Pretax Income
794000000
Net Income
636000000
Eps
1.845572729141805
Dividends Per Share
-
Shares Outstanding
689312600
Income Tax Expense
-
EBITDA
-
Operating Margin
16.356275303643724
Total Other Income Expense Net
-
Cash
1058000000
Short Term Investments
-
Receivables
5407000000
Inventories
4258000000
Total Current Assets
12300000000
Property Plant Equipment
1635000000
Total Assets
68750000000
Payables
997000000
Short Term Debt
-
Long Term Debt
8525000000
Total Liabilities
29682000000
Equity
39061000000
Bs_currency_symbol
SEK
Depreciation
889000000
Change In Working Capital
-190000000
Cash From Operations
1448000000
Capital Expenditures
421000000
Cash From Investing
-
Cash From Financing
-
Net Change In Cash
35000000
Cf_currency_symbol
SEK
PE
0
PB
0.1490971350887074
ROE
1.6282225237449117
ROA
0.9250909090909091
FCF
1027000000
Fcf Percent
0.16631578947368422
Piotroski FScore
4
Health Score
63
Deep Value Investing Score
8.5
Defensive Investing Score
6.5
Dividend Investing Score
3
Economic Moat Investing Score
7.8
Garp Investing Score
3.5
Growth Investing Score
3
Momentum Investing Score
7
Net Net Investing Score
4
Quality Investing Score
5
Value Investing Score
9
Quarters > 0 > quarter
2025-06-30
Quarters > 0 > income Statement > revenue
6175000000
Quarters > 0 > income Statement > cost Of Revenue
1426000000
Quarters > 0 > income Statement > gross Profit
4749000000
Quarters > 0 > income Statement > operating Expenses
5165000000
Quarters > 0 > income Statement > operating Income
1010000000
Quarters > 0 > income Statement > interest Expense
-
Quarters > 0 > income Statement > pretax Income
794000000
Quarters > 0 > income Statement > net Income
636000000
Quarters > 0 > income Statement > eps
1.845572729141805
Quarters > 0 > income Statement > dividends Per Share
-
Quarters > 0 > income Statement > shares Outstanding
344608473
Quarters > 0 > income Statement > income Tax Expense
-
Quarters > 0 > income Statement > EBITDA
-
Quarters > 0 > income Statement > operating Margin
16.356275303643724
Quarters > 0 > income Statement > total Other Income Expense Net
-
Quarters > 0 > income Statement > currency_symbol
SEK
Quarters > 0 > balance Sheet > cash
1058000000
Quarters > 0 > balance Sheet > short Term Investments
-
Quarters > 0 > balance Sheet > receivables
5407000000
Quarters > 0 > balance Sheet > inventories
4258000000
Quarters > 0 > balance Sheet > total Current Assets
12300000000
Quarters > 0 > balance Sheet > property Plant Equipment
1635000000
Quarters > 0 > balance Sheet > total Assets
68750000000
Quarters > 0 > balance Sheet > payables
997000000
Quarters > 0 > balance Sheet > short Term Debt
-
Quarters > 0 > balance Sheet > long Term Debt
8525000000
Quarters > 0 > balance Sheet > total Liabilities
29682000000
Quarters > 0 > balance Sheet > equity
39061000000
Quarters > 0 > balance Sheet > currency_symbol
SEK
Quarters > 0 > cash Flow > net Income
634000000
Quarters > 0 > cash Flow > depreciation
889000000
Quarters > 0 > cash Flow > change In Working Capital
-190000000
Quarters > 0 > cash Flow > cash From Operations
1448000000
Quarters > 0 > cash Flow > capital Expenditures
421000000
Quarters > 0 > cash Flow > cash From Investing
-
Quarters > 0 > cash Flow > cash From Financing
-
Quarters > 0 > cash Flow > net Change In Cash
35000000
Quarters > 0 > cash Flow > currency_symbol
SEK
Quarters > 0 > ratios > PE
1.845572729141805
Quarters > 0 > ratios > PB
0.1490971350887074
Quarters > 0 > ratios > ROE
1.6282225237449117
Quarters > 0 > ratios > ROA
0.9250909090909091
Quarters > 0 > ratios > FCF
1027000000
Quarters > 0 > ratios > Piotroski FScore
4
Quarters > 0 > ratios > fcf Percent
0.16631578947368422
Quarters > 0 > health Score
63
Quarters > 1 > quarter
2025-03-31
Quarters > 1 > income Statement > revenue
6465000000
Quarters > 1 > income Statement > cost Of Revenue
1589000000
Quarters > 1 > income Statement > gross Profit
4877000000
Quarters > 1 > income Statement > operating Expenses
5108000000
Quarters > 1 > income Statement > operating Income
1358000000
Quarters > 1 > income Statement > interest Expense
-
Quarters > 1 > income Statement > pretax Income
1096000000
Quarters > 1 > income Statement > net Income
875000000
Quarters > 1 > income Statement > eps
2.5476249588715065
Quarters > 1 > income Statement > dividends Per Share
-
Quarters > 1 > income Statement > shares Outstanding
343457147
Quarters > 1 > income Statement > income Tax Expense
-
Quarters > 1 > income Statement > EBITDA
-
Quarters > 1 > income Statement > operating Margin
21.005413766434646
Quarters > 1 > income Statement > total Other Income Expense Net
-
Quarters > 1 > income Statement > currency_symbol
SEK
Quarters > 1 > balance Sheet > cash
997000000
Quarters > 1 > balance Sheet > short Term Investments
-
Quarters > 1 > balance Sheet > receivables
5135000000
Quarters > 1 > balance Sheet > inventories
3884000000
Quarters > 1 > balance Sheet > total Current Assets
11715000000
Quarters > 1 > balance Sheet > property Plant Equipment
1577000000
Quarters > 1 > balance Sheet > total Assets
70120000000
Quarters > 1 > balance Sheet > payables
1069000000
Quarters > 1 > balance Sheet > short Term Debt
-
Quarters > 1 > balance Sheet > long Term Debt
9746000000
Quarters > 1 > balance Sheet > total Liabilities
31083000000
Quarters > 1 > balance Sheet > equity
39029000000
Quarters > 1 > balance Sheet > currency_symbol
SEK
Quarters > 1 > cash Flow > net Income
875000000
Quarters > 1 > cash Flow > depreciation
938000000
Quarters > 1 > cash Flow > change In Working Capital
1024000000
Quarters > 1 > cash Flow > cash From Operations
2295000000
Quarters > 1 > cash Flow > capital Expenditures
11000000
Quarters > 1 > cash Flow > cash From Investing
-
Quarters > 1 > cash Flow > cash From Financing
-
Quarters > 1 > cash Flow > net Change In Cash
-92000000
Quarters > 1 > cash Flow > currency_symbol
SEK
Quarters > 1 > ratios > PE
2.5476249588715065
Quarters > 1 > ratios > PB
0.14872084307309946
Quarters > 1 > ratios > ROE
2.241922672884266
Quarters > 1 > ratios > ROA
1.2478608100399315
Quarters > 1 > ratios > FCF
2284000000
Quarters > 1 > ratios > Piotroski FScore
4
Quarters > 1 > ratios > fcf Percent
0.35328692962103636
Quarters > 1 > health Score
67
Quarters > 2 > quarter
2024-12-31
Quarters > 2 > income Statement > revenue
7436000000
Quarters > 2 > income Statement > cost Of Revenue
1600000000
Quarters > 2 > income Statement > gross Profit
5836000000
Quarters > 2 > income Statement > operating Expenses
5775000000
Quarters > 2 > income Statement > operating Income
1661000000
Quarters > 2 > income Statement > interest Expense
-
Quarters > 2 > income Statement > pretax Income
1437000000
Quarters > 2 > income Statement > net Income
1397000000
Quarters > 2 > income Statement > eps
4.06763481480427
Quarters > 2 > income Statement > dividends Per Share
-
Quarters > 2 > income Statement > shares Outstanding
343442827
Quarters > 2 > income Statement > income Tax Expense
-
Quarters > 2 > income Statement > EBITDA
-
Quarters > 2 > income Statement > operating Margin
22.337278106508876
Quarters > 2 > income Statement > total Other Income Expense Net
-
Quarters > 2 > income Statement > currency_symbol
SEK
Quarters > 2 > balance Sheet > cash
1140000000
Quarters > 2 > balance Sheet > short Term Investments
-
Quarters > 2 > balance Sheet > receivables
5196000000
Quarters > 2 > balance Sheet > inventories
4159000000
Quarters > 2 > balance Sheet > total Current Assets
13162000000
Quarters > 2 > balance Sheet > property Plant Equipment
1584000000
Quarters > 2 > balance Sheet > total Assets
75444000000
Quarters > 2 > balance Sheet > payables
944000000
Quarters > 2 > balance Sheet > short Term Debt
-
Quarters > 2 > balance Sheet > long Term Debt
12407000000
Quarters > 2 > balance Sheet > total Liabilities
35149000000
Quarters > 2 > balance Sheet > equity
40286000000
Quarters > 2 > balance Sheet > currency_symbol
SEK
Quarters > 2 > cash Flow > net Income
1397000000
Quarters > 2 > cash Flow > depreciation
932000000
Quarters > 2 > cash Flow > change In Working Capital
-127000000
Quarters > 2 > cash Flow > cash From Operations
1797000000
Quarters > 2 > cash Flow > capital Expenditures
61000000
Quarters > 2 > cash Flow > cash From Investing
-
Quarters > 2 > cash Flow > cash From Financing
-
Quarters > 2 > cash Flow > net Change In Cash
546000000
Quarters > 2 > cash Flow > currency_symbol
SEK
Quarters > 2 > ratios > PE
4.06763481480427
Quarters > 2 > ratios > PB
0.14407446200417018
Quarters > 2 > ratios > ROE
3.467705902795016
Quarters > 2 > ratios > ROA
1.8517045755792376
Quarters > 2 > ratios > FCF
1736000000
Quarters > 2 > ratios > Piotroski FScore
4
Quarters > 2 > ratios > fcf Percent
0.23345884884346424
Quarters > 2 > health Score
69
Quarters > 3 > quarter
2024-09-30
Quarters > 3 > income Statement > revenue
6894000000
Quarters > 3 > income Statement > cost Of Revenue
1331000000
Quarters > 3 > income Statement > gross Profit
5563000000
Quarters > 3 > income Statement > operating Expenses
4855000000
Quarters > 3 > income Statement > operating Income
2039000000
Quarters > 3 > income Statement > interest Expense
-
Quarters > 3 > income Statement > pretax Income
1712000000
Quarters > 3 > income Statement > net Income
1464000000
Quarters > 3 > income Statement > eps
4.262805003261221
Quarters > 3 > income Statement > dividends Per Share
-
Quarters > 3 > income Statement > shares Outstanding
343435836
Quarters > 3 > income Statement > income Tax Expense
-
Quarters > 3 > income Statement > EBITDA
-
Quarters > 3 > income Statement > operating Margin
29.576443284015085
Quarters > 3 > income Statement > total Other Income Expense Net
-
Quarters > 3 > income Statement > currency_symbol
SEK
Quarters > 3 > balance Sheet > cash
594000000
Quarters > 3 > balance Sheet > short Term Investments
-
Quarters > 3 > balance Sheet > receivables
4675000000
Quarters > 3 > balance Sheet > inventories
3994000000
Quarters > 3 > balance Sheet > total Current Assets
12647000000
Quarters > 3 > balance Sheet > property Plant Equipment
384000000
Quarters > 3 > balance Sheet > total Assets
72195000000
Quarters > 3 > balance Sheet > payables
1366000000
Quarters > 3 > balance Sheet > short Term Debt
-
Quarters > 3 > balance Sheet > long Term Debt
11473000000
Quarters > 3 > balance Sheet > total Liabilities
35086000000
Quarters > 3 > balance Sheet > equity
37094000000
Quarters > 3 > balance Sheet > currency_symbol
SEK
Quarters > 3 > cash Flow > net Income
1464000000
Quarters > 3 > cash Flow > depreciation
924000000
Quarters > 3 > cash Flow > change In Working Capital
-1652000000
Quarters > 3 > cash Flow > cash From Operations
1201000000
Quarters > 3 > cash Flow > capital Expenditures
2180000000
Quarters > 3 > cash Flow > cash From Investing
-
Quarters > 3 > cash Flow > cash From Financing
-
Quarters > 3 > cash Flow > net Change In Cash
-141000000
Quarters > 3 > cash Flow > currency_symbol
SEK
Quarters > 3 > ratios > PE
4.262805003261221
Quarters > 3 > ratios > PB
0.15646912245646197
Quarters > 3 > ratios > ROE
3.946729929368631
Quarters > 3 > ratios > ROA
2.027841263245377
Quarters > 3 > ratios > FCF
-979000000
Quarters > 3 > ratios > Piotroski FScore
3
Quarters > 3 > ratios > fcf Percent
-0.1420075427908326
Quarters > 3 > health Score
50
Annuals > 0 > quarter
2024-12-31
Annuals > 0 > income Statement > revenue
26027000000
Annuals > 0 > income Statement > cost Of Revenue
5785000000
Annuals > 0 > income Statement > gross Profit
20242000000
Annuals > 0 > income Statement > operating Expenses
20410000000
Annuals > 0 > income Statement > operating Income
5617000000
Annuals > 0 > income Statement > interest Expense
1239000000
Annuals > 0 > income Statement > pretax Income
4407000000
Annuals > 0 > income Statement > net Income
3885000000
Annuals > 0 > income Statement > eps
11.311926453482169
Annuals > 0 > income Statement > dividends Per Share
-
Annuals > 0 > income Statement > shares Outstanding
343442827
Annuals > 0 > income Statement > income Tax Expense
-
Annuals > 0 > income Statement > EBITDA
-
Annuals > 0 > income Statement > operating Margin
21.581434664002767
Annuals > 0 > income Statement > total Other Income Expense Net
-
Annuals > 0 > income Statement > currency_symbol
SEK
Annuals > 0 > balance Sheet > cash
1140000000
Annuals > 0 > balance Sheet > short Term Investments
-
Annuals > 0 > balance Sheet > receivables
5196000000
Annuals > 0 > balance Sheet > inventories
4159000000
Annuals > 0 > balance Sheet > total Current Assets
13162000000
Annuals > 0 > balance Sheet > property Plant Equipment
1584000000
Annuals > 0 > balance Sheet > total Assets
75444000000
Annuals > 0 > balance Sheet > payables
944000000
Annuals > 0 > balance Sheet > short Term Debt
-
Annuals > 0 > balance Sheet > long Term Debt
12407000000
Annuals > 0 > balance Sheet > total Liabilities
35149000000
Annuals > 0 > balance Sheet > equity
40286000000
Annuals > 0 > balance Sheet > currency_symbol
SEK
Annuals > 0 > cash Flow > net Income
3885000000
Annuals > 0 > cash Flow > depreciation
3679000000
Annuals > 0 > cash Flow > change In Working Capital
-180000000
Annuals > 0 > cash Flow > cash From Operations
7388000000
Annuals > 0 > cash Flow > capital Expenditures
3005000000
Annuals > 0 > cash Flow > cash From Investing
-
Annuals > 0 > cash Flow > cash From Financing
-
Annuals > 0 > cash Flow > net Change In Cash
296000000
Annuals > 0 > cash Flow > currency_symbol
SEK
Annuals > 0 > ratios > PE
11.311926453482169
Annuals > 0 > ratios > PB
0.15174706648959937
Annuals > 0 > ratios > ROE
9.6435486273147
Annuals > 0 > ratios > ROA
5.149514871958009
Annuals > 0 > ratios > FCF
4383000000
Annuals > 0 > ratios > Piotroski FScore
4
Annuals > 0 > ratios > fcf Percent
0.16840204403119838
Annuals > 0 > health Score
71
Annuals > 1 > quarter
2023-12-31
Annuals > 1 > income Statement > revenue
22123000000
Annuals > 1 > income Statement > cost Of Revenue
4995000000
Annuals > 1 > income Statement > gross Profit
17128000000
Annuals > 1 > income Statement > operating Expenses
17943000000
Annuals > 1 > income Statement > operating Income
4180000000
Annuals > 1 > income Statement > interest Expense
1111000000
Annuals > 1 > income Statement > pretax Income
2954000000
Annuals > 1 > income Statement > net Income
2409000000
Annuals > 1 > income Statement > eps
7.090359261763685
Annuals > 1 > income Statement > dividends Per Share
-
Annuals > 1 > income Statement > shares Outstanding
339757114
Annuals > 1 > income Statement > income Tax Expense
-
Annuals > 1 > income Statement > EBITDA
-
Annuals > 1 > income Statement > operating Margin
18.894363332278623
Annuals > 1 > income Statement > total Other Income Expense Net
-
Annuals > 1 > income Statement > currency_symbol
SEK
Annuals > 1 > balance Sheet > cash
904000000
Annuals > 1 > balance Sheet > short Term Investments
-
Annuals > 1 > balance Sheet > receivables
5169000000
Annuals > 1 > balance Sheet > inventories
3874000000
Annuals > 1 > balance Sheet > total Current Assets
12671000000
Annuals > 1 > balance Sheet > property Plant Equipment
251000000
Annuals > 1 > balance Sheet > total Assets
74027000000
Annuals > 1 > balance Sheet > payables
1024000000
Annuals > 1 > balance Sheet > short Term Debt
-
Annuals > 1 > balance Sheet > long Term Debt
11356000000
Annuals > 1 > balance Sheet > total Liabilities
40160000000
Annuals > 1 > balance Sheet > equity
33867000000
Annuals > 1 > balance Sheet > currency_symbol
SEK
Annuals > 1 > cash Flow > net Income
2409000000
Annuals > 1 > cash Flow > depreciation
2827000000
Annuals > 1 > cash Flow > change In Working Capital
-639000000
Annuals > 1 > cash Flow > cash From Operations
5380000000
Annuals > 1 > cash Flow > capital Expenditures
4548000000
Annuals > 1 > cash Flow > cash From Investing
-
Annuals > 1 > cash Flow > cash From Financing
-
Annuals > 1 > cash Flow > net Change In Cash
380000000
Annuals > 1 > cash Flow > currency_symbol
SEK
Annuals > 1 > ratios > PE
7.090359261763685
Annuals > 1 > ratios > PB
0.1785713712227242
Annuals > 1 > ratios > ROE
7.113118965364514
Annuals > 1 > ratios > ROA
3.254218055574318
Annuals > 1 > ratios > FCF
832000000
Annuals > 1 > ratios > Piotroski FScore
4
Annuals > 1 > ratios > fcf Percent
0.03760791935994214
Annuals > 1 > health Score
51
Annuals > 2 > quarter
2022-12-31
Annuals > 2 > income Statement > revenue
18790000000
Annuals > 2 > income Statement > cost Of Revenue
4776000000
Annuals > 2 > income Statement > gross Profit
14014000000
Annuals > 2 > income Statement > operating Expenses
14945000000
Annuals > 2 > income Statement > operating Income
3845000000
Annuals > 2 > income Statement > interest Expense
458000000
Annuals > 2 > income Statement > pretax Income
3321000000
Annuals > 2 > income Statement > net Income
2638000000
Annuals > 2 > income Statement > eps
8.911708778978031
Annuals > 2 > income Statement > dividends Per Share
-
Annuals > 2 > income Statement > shares Outstanding
296015059
Annuals > 2 > income Statement > income Tax Expense
683000000
Annuals > 2 > income Statement > EBITDA
-
Annuals > 2 > income Statement > operating Margin
20.463012240553486
Annuals > 2 > income Statement > total Other Income Expense Net
-
Annuals > 2 > income Statement > currency_symbol
USD
Annuals > 2 > balance Sheet > cash
1361000000
Annuals > 2 > balance Sheet > short Term Investments
-
Annuals > 2 > balance Sheet > receivables
5248000000
Annuals > 2 > balance Sheet > inventories
3332000000
Annuals > 2 > balance Sheet > total Current Assets
11210000000
Annuals > 2 > balance Sheet > property Plant Equipment
274000000
Annuals > 2 > balance Sheet > total Assets
52496000000
Annuals > 2 > balance Sheet > payables
1252000000
Annuals > 2 > balance Sheet > short Term Debt
-
Annuals > 2 > balance Sheet > long Term Debt
2971000000
Annuals > 2 > balance Sheet > total Liabilities
25971000000
Annuals > 2 > balance Sheet > equity
26525000000
Annuals > 2 > balance Sheet > currency_symbol
SEK
Annuals > 2 > cash Flow > net Income
2638000000
Annuals > 2 > cash Flow > depreciation
2283000000
Annuals > 2 > cash Flow > change In Working Capital
-806000000
Annuals > 2 > cash Flow > cash From Operations
4670000000
Annuals > 2 > cash Flow > capital Expenditures
72000000
Annuals > 2 > cash Flow > cash From Investing
-1477000000
Annuals > 2 > cash Flow > cash From Financing
-2991000000
Annuals > 2 > cash Flow > net Change In Cash
321000000
Annuals > 2 > cash Flow > currency_symbol
SEK
Annuals > 2 > ratios > PE
8.911708778978031
Annuals > 2 > ratios > PB
0.198645355332705
Annuals > 2 > ratios > ROE
9.945334590009425
Annuals > 2 > ratios > ROA
5.02514477293508
Annuals > 2 > ratios > FCF
4598000000
Annuals > 2 > ratios > Piotroski FScore
4
Annuals > 2 > ratios > fcf Percent
0.24470463012240554
Annuals > 2 > health Score
77
Annuals > 3 > quarter
2021-12-31
Annuals > 3 > income Statement > revenue
15529000000
Annuals > 3 > income Statement > cost Of Revenue
3484000000
Annuals > 3 > income Statement > gross Profit
12045000000
Annuals > 3 > income Statement > operating Expenses
11742000000
Annuals > 3 > income Statement > operating Income
3787000000
Annuals > 3 > income Statement > interest Expense
419000000
Annuals > 3 > income Statement > pretax Income
3295000000
Annuals > 3 > income Statement > net Income
2679000000
Annuals > 3 > income Statement > eps
9.076905817588163
Annuals > 3 > income Statement > dividends Per Share
-
Annuals > 3 > income Statement > shares Outstanding
295144629
Annuals > 3 > income Statement > income Tax Expense
616000000
Annuals > 3 > income Statement > EBITDA
-
Annuals > 3 > income Statement > operating Margin
24.386631463713055
Annuals > 3 > income Statement > total Other Income Expense Net
-
Annuals > 3 > income Statement > currency_symbol
USD
Annuals > 3 > balance Sheet > cash
1045000000
Annuals > 3 > balance Sheet > short Term Investments
-
Annuals > 3 > balance Sheet > receivables
3438000000
Annuals > 3 > balance Sheet > inventories
3424000000
Annuals > 3 > balance Sheet > total Current Assets
8778000000
Annuals > 3 > balance Sheet > property Plant Equipment
493000000
Annuals > 3 > balance Sheet > total Assets
48661000000
Annuals > 3 > balance Sheet > payables
558000000
Annuals > 3 > balance Sheet > short Term Debt
-
Annuals > 3 > balance Sheet > long Term Debt
8777000000
Annuals > 3 > balance Sheet > total Liabilities
25458000000
Annuals > 3 > balance Sheet > equity
23203000000
Annuals > 3 > balance Sheet > currency_symbol
SEK
Annuals > 3 > cash Flow > net Income
2679000000
Annuals > 3 > cash Flow > depreciation
1924000000
Annuals > 3 > cash Flow > change In Working Capital
1114000000
Annuals > 3 > cash Flow > cash From Operations
5470000000
Annuals > 3 > cash Flow > capital Expenditures
47000000
Annuals > 3 > cash Flow > cash From Investing
-367000000
Annuals > 3 > cash Flow > cash From Financing
-4474000000
Annuals > 3 > cash Flow > net Change In Cash
641000000
Annuals > 3 > cash Flow > currency_symbol
SEK
Annuals > 3 > ratios > PE
9.076905817588163
Annuals > 3 > ratios > PB
0.22641789407404217
Annuals > 3 > ratios > ROE
11.545920786105244
Annuals > 3 > ratios > ROA
5.505435564415034
Annuals > 3 > ratios > FCF
5423000000
Annuals > 3 > ratios > Piotroski FScore
4
Annuals > 3 > ratios > fcf Percent
0.3492175928907206
Annuals > 3 > health Score
73
Valuation > metrics > PE
1.845572729141805
Valuation > metrics > PB
0.1490971350887074
Valuation > final Score
90
Valuation > verdict
83.3% Undervalued
Profitability > metrics > ROE
1.6282225237449117
Profitability > metrics > ROA
5.170731707317073
Profitability > metrics > Net Margin
0.10299595141700404
Profitability > final Score
34
Profitability > verdict
Weak
Risk > metrics > Debt Equity
0.759888379713781
Risk > final Score
68
Risk > verdict
High
Liquidity > metrics > Current Ratio
12.337011033099298
Liquidity > metrics > Quick Ratio
8.066198595787363
Liquidity > final Score
100
Liquidity > verdict
Great
Prev Valuations > 0
90
Prev Valuations > 1
90
Prev Valuations > 2
90
Prev Profitabilities > 0
47
Prev Profitabilities > 1
65
Prev Profitabilities > 2
68
Prev Risks > 0
68
Prev Risks > 1
68
Prev Risks > 2
68
Prev Liquidities > 0
100
Prev Liquidities > 1
100
Prev Liquidities > 2
100
Updated At
2026-01-20T22:39:22.796Z
Earnings History > 0 > period
2026-03-31
Earnings History > 0 > report Date
2026-04-27
Earnings History > 0 > date
2026-03-31
Earnings History > 0 > before After Market
BeforeMarket
Earnings History > 0 > currency
-
Earnings History > 0 > eps Actual
-
Earnings History > 0 > eps Estimate
-
Earnings History > 0 > eps Difference
0
Earnings History > 0 > surprise Percent
-
Earnings History > 1 > period
2025-12-31
Earnings History > 1 > report Date
2026-02-03
Earnings History > 1 > date
2025-12-31
Earnings History > 1 > before After Market
BeforeMarket
Earnings History > 1 > currency
-
Earnings History > 1 > eps Actual
-
Earnings History > 1 > eps Estimate
-
Earnings History > 1 > eps Difference
0
Earnings History > 1 > surprise Percent
-
Earnings History > 2 > period
2025-09-30
Earnings History > 2 > report Date
2025-10-23
Earnings History > 2 > date
2025-09-30
Earnings History > 2 > before After Market
BeforeMarket
Earnings History > 2 > currency
-
Earnings History > 2 > eps Actual
-0.4411
Earnings History > 2 > eps Estimate
-
Earnings History > 2 > eps Difference
0
Earnings History > 2 > surprise Percent
-
Earnings History > 3 > period
2025-06-30
Earnings History > 3 > report Date
2025-07-16
Earnings History > 3 > date
2025-06-30
Earnings History > 3 > before After Market
BeforeMarket
Earnings History > 3 > currency
SEK
Earnings History > 3 > eps Actual
0.0948
Earnings History > 3 > eps Estimate
-
Earnings History > 3 > eps Difference
0
Earnings History > 3 > surprise Percent
-
Earnings History > 4 > period
2025-03-31
Earnings History > 4 > report Date
2025-04-29
Earnings History > 4 > date
2025-03-31
Earnings History > 4 > before After Market
BeforeMarket
Earnings History > 4 > currency
SEK
Earnings History > 4 > eps Actual
0.1181
Earnings History > 4 > eps Estimate
-
Earnings History > 4 > eps Difference
0
Earnings History > 4 > surprise Percent
-
Earnings History > 5 > period
2024-12-31
Earnings History > 5 > report Date
2025-02-05
Earnings History > 5 > date
2024-12-31
Earnings History > 5 > before After Market
BeforeMarket
Earnings History > 5 > currency
-
Earnings History > 5 > eps Actual
0.1867
Earnings History > 5 > eps Estimate
-
Earnings History > 5 > eps Difference
0
Earnings History > 5 > surprise Percent
-
Earnings History > 6 > period
2024-09-30
Earnings History > 6 > report Date
2024-10-24
Earnings History > 6 > date
2024-09-30
Earnings History > 6 > before After Market
BeforeMarket
Earnings History > 6 > currency
SEK
Earnings History > 6 > eps Actual
0.2025
Earnings History > 6 > eps Estimate
-
Earnings History > 6 > eps Difference
0
Earnings History > 6 > surprise Percent
-
Earnings History > 7 > period
2024-06-30
Earnings History > 7 > report Date
2024-07-16
Earnings History > 7 > date
2024-06-30
Earnings History > 7 > before After Market
BeforeMarket
Earnings History > 7 > currency
SEK
Earnings History > 7 > eps Actual
0.0304
Earnings History > 7 > eps Estimate
-
Earnings History > 7 > eps Difference
0
Earnings History > 7 > surprise Percent
-
Earnings History > 8 > period
2024-03-31
Earnings History > 8 > report Date
2024-04-25
Earnings History > 8 > date
2024-03-31
Earnings History > 8 > before After Market
BeforeMarket
Earnings History > 8 > currency
SEK
Earnings History > 8 > eps Actual
0.1118
Earnings History > 8 > eps Estimate
-
Earnings History > 8 > eps Difference
0
Earnings History > 8 > surprise Percent
-
Earnings History > 9 > period
2023-12-31
Earnings History > 9 > report Date
2024-02-08
Earnings History > 9 > date
2023-12-31
Earnings History > 9 > before After Market
BeforeMarket
Earnings History > 9 > currency
SEK
Earnings History > 9 > eps Actual
0.1402
Earnings History > 9 > eps Estimate
-
Earnings History > 9 > eps Difference
0
Earnings History > 9 > surprise Percent
-
Earnings History > 10 > period
2023-09-30
Earnings History > 10 > report Date
2023-10-30
Earnings History > 10 > date
2023-09-30
Earnings History > 10 > before After Market
-
Earnings History > 10 > currency
SEK
Earnings History > 10 > eps Actual
0.0136
Earnings History > 10 > eps Estimate
-
Earnings History > 10 > eps Difference
0
Earnings History > 10 > surprise Percent
-
Earnings History > 11 > period
2023-06-30
Earnings History > 11 > report Date
2023-07-18
Earnings History > 11 > date
2023-06-30
Earnings History > 11 > before After Market
-
Earnings History > 11 > currency
SEK
Earnings History > 11 > eps Actual
0.0335
Earnings History > 11 > eps Estimate
-
Earnings History > 11 > eps Difference
0
Earnings History > 11 > surprise Percent
-
Earnings History > 12 > period
2023-03-31
Earnings History > 12 > report Date
2023-04-27
Earnings History > 12 > date
2023-03-31
Earnings History > 12 > before After Market
-
Earnings History > 12 > currency
-
Earnings History > 12 > eps Actual
0.1631
Earnings History > 12 > eps Estimate
-
Earnings History > 12 > eps Difference
0
Earnings History > 12 > surprise Percent
-
Swedish Orphan Biovitrum AB (publ), a biopharma company, provides medicines in the areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. The company operates through three segments: Haematology, Immunology, and Specialty Care. It offers Alprolix for haemophilia B; ALTUVOCT for the treatment and prophylaxis of bleeding in patients with haemophilia A; Aspaveli/Empaveli for treating adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet for the treatment of immune thrombocytopenia and thrombocytopenia; Elocta/Eloctate for the treatment and prophylaxis of bleeding in patients with haemophilia A; Gamifant for treating hemophagocytic lymphohistiocytosis; Kineret for the treatment of cryopyrin-associated periodic syndrome, rheumatoid arthritis, familial Mediterranean fever, deficiency of interleukin-1 receptor antagonist, and systemic juvenile idiopathic arthritis; Orfadin for hereditary tyrosinemia type 1 and alkaptonuria; Synagis for the prevention of serious lower respiratory tract infection caused by respiratory syncytial virus in infants and young children; VONJO, a kinase inhibitor indicated for the treatment of post-polycythemia vera or post-essential thrombocythemia myelofibrosis; and Zynlonta for treating adult patients with relapsed or refractory diffuse large and high grade B-cell lymphoma. The company also provides other medicines, such as Akynzeo, Aloxi, Jyseleca, Kepivance, Tegsedi, and Waylivra, as well as develops drug substances for ReFacto AF/Xyntha for Pfizer. The company has collaboration agreements with Sanofi, Apellis Pharmaceuticals, Inc., ADC Therapeutics SA, and Cartesian Therapeutics, Inc. Swedish Orphan Biovitrum AB (publ) was incorporated in 1939 and is headquartered in Stockholm, Sweden.
Stock Price
$0.00
decrease compared to yesterday.
Dividend
Frequency:
Rate:
N/ANext Payout:
N/ASobi, Apellis win EU nod for Aspaveli against rare kidney diseases Seeking Alpha
Read more →Showing 2 of 5
(Last Updated 2025-06-30)
Rating:
STRONG SELL
$
Analyst Picks
Strong Buy
0
Buy
0
Hold
0
Sell
0
Strong Sell
1
Sentiment:
Bullish
(Last Updated 2025-06-30)
Health Score
Price to Book Ratio (P/B)
-
Very Low
Low ≤ 1
High ≥ 3
Return on Equity (ROE)
-
Very Low
Low ≤ 5%
High ≥ 25%
Return on Assets (ROA)
-
Very Low
Low ≤ 2%
High ≥ 10%
Free Cash Flow - Revenue % (FCF)
-
Very High
Low ≤ 5%
High ≥ 15%
Debt to Equity
-
Low
Low ≥ 1
High ≤ 0.3
* Institutions hold a combined 0.00% of the total shares of Swedish Orphan Biovitrum AB (publ)
* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.
Date
2025-12-31
EPS Estimate
—
Date
2025-09-30
EPS Actual
-0.4411
EPS Estimate
—
EPS Difference
0
Surprise Percent
0%
(Last Updated 2025-06-30)
(Last Updated 2025-06-30)
Revenue
$ 0
Cost Of Revenue
$ 0
Gross Profit
$ 0
Operating Expenses
$ 0
Operating Income
$ 0
Interest Expense
$ 0
Pretax Income
$ 0
Net Income
$ 0
Income Tax Expense
$ 0
EBITDA
$ 0
Total Other Income Expense Net
$ 0
Earnings Per Share
0
Dividends Per Share
0
Shares Outstanding
0
Operating Margin
0%
(Last Updated 2025-06-30)
Cash
$ 0
Short Term Investments
$ 0
Receivables
$ 0
Inventories
$ 0
Total Current Assets
$ 0
Property Plant Equipment
$ 0
Total Assets
$ 0
Payables
$ 0
Short Term Debt
$ 0
Long Term Debt
$ 0
Total Liabilities
$ 0
Equity
$ 0
(Last Updated 2025-06-30)
Net Income
$ 0
Depreciation
$ 0
Change In Working Capital
$ 0
Cash From Operations
$ 0
Capital Expenditures
$ 0
Cash From Investing
$ 0
Cash From Financing
$ 0
Net Change In Cash
$ 0
Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.